Drug Trial Radar · NCT07079475
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Jul 30, 2025
Primary completion
Jun 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Dizal PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jul 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will treat patients with advanced NSCLC harboring EGFR mutations. This is the first study to test DZD6008 combined with sunvozertinib in patients, which will help to understand what type of side effects with the treatment. It will also measure the levels of two drugs in the body and preliminarily assess the anti-tumor activity with the combination treatment
Conditions
- Non-Small Cell Lung Cancer
Interventions
DZD6008Drug
DZD6008 will be administered orally at 40/60 mg QD or selected dose.
SunvozertinibDrug
Sunvozertinib will be administered orally at 100/200 mg QD or selected dose.
OsimertinibDrug
Osimertinib will be administered orally at 80 mg QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: To assess safety and tolerabilityTime frame: Through the study completion, an average of around 2 years
- Part A: To assess safety and tolerabilityTime frame: 21 days after the first dose
- Part B: To assess anti-tumor activityTime frame: Through the study completion, an average of around 2 years
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chest Hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China · Recruiting
Harbin Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Not yet recruiting
Jiangsu People's Hospital
Nanjing, Jiangsu, China · Not yet recruiting
Nanjing Gulou Hospital
Nanjing, Jiangsu, China · Recruiting
First Affilicated Hospital of China Medical University
Shengyang, Liaoning, China · Not yet recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Recruiting
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Sichuan Cancer Hospital
Chengdu, Sichuan, China · Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Zhejiang Taizhou Hospital
Taizhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.